Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.

MLA

Heinzl, Nicole, et al. “Amyloid-like P53 as Prognostic Biomarker in Serous Ovarian Cancer-a Study of the OVCAD Consortium.” Oncogene, vol. 42, no. 33, Aug. 2023, pp. 2473–84. EBSCOhost, https://doi.org/10.1038/s41388-023-02758-8.

APA

Heinzl, N., Maritschnegg, E., Koziel, K., Schilhart-Wallisch, C., Heinze, G., Yang, W.-L., Bast, R. C., Sehouli, J., Braicu, E. I., Vergote, I., Van Gorp, T., Mahner, S., Paspalj, V., Grimm, C., Obermayr, E., Schuster, E., Holzer, B., Rousseau, F., Schymkowitz, J., … Zeillinger, R. (2023). Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium. Oncogene, 42(33), 2473–2484. https://doi.org/10.1038/s41388-023-02758-8

Chicago

Heinzl, Nicole, Elisabeth Maritschnegg, Katarzyna Koziel, Christine Schilhart-Wallisch, Georg Heinze, Wei-Lei Yang, Robert C Bast, et al. 2023. “Amyloid-like P53 as Prognostic Biomarker in Serous Ovarian Cancer-a Study of the OVCAD Consortium.” Oncogene 42 (33): 2473–84. doi:10.1038/s41388-023-02758-8.